ReviewPeptides2018
Problem or solution: The strange story of glucagon.
Review in Peptides, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 54 citations in OpenAlex.
- Non-carbohydrate anaplerotic therapy counters empagliflozin-induced diabetic ketosis.Nutrition & diabetes · 2025Article
- Relationship between glucagon and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus.World journal of hepatology · 2025Article
- Retatrutide-A Game Changer in Obesity Pharmacotherapy.Biomolecules · 2025Review
- A tumor-secreted protein utilizes glucagon release to cause host wasting.Cell discovery · 2025Article
- Comparative Effect of Insulin Resistance Reduction and Hormonal Alterations on Type 2 Diabetes Remission After Bariatric Surgery.Journal of clinical medicine · 2024Article
- Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes.Current atherosclerosis reports · 2024Review
- Larval density can be used to predict genetic modifiers of glucagon signaling in Drosophila melanogaster.PloS one · 2024Article
- The impact of macronutrient composition on metabolic regulation: An Islet-Centric view.Acta physiologica (Oxford, England) · 2022Article
- Review
- Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.Obesity pillars · 2022Article
- Introduction to special issue on feeding peptides.Peptides · 2022Article
- A glucagon analogue decreases body weight in mice via signalling in the liver.Scientific reports · 2021Article
- The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes.Journal of clinical medicine · 2021Article
- Menthol to Induce Non-shivering Thermogenesis via TRPM8/PKA Signaling for Treatment of Obesity.Journal of obesity & metabolic syndrome · 2021Review
- Greater Loss of Central Adiposity from Low-Carbohydrate versus Low-Fat Diet in Middle-Aged Adults with Overweight and Obesity.Nutrients · 2021Article
- Proglucagon-Derived Peptides as Therapeutics.Frontiers in endocrinology · 2021Review
- Genome-wide association study of pancreatic fat: The Multiethnic Cohort Adiposity Phenotype Study.PloS one · 2021Article
- A combined activation mechanism for the glucagon receptor.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome.Current diabetes reports · 2020Review
- Signal Transduction Mechanisms for Glucagon-Induced Somatolactin Secretion and Gene Expression in Nile Tilapia (Frontiers in endocrinology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Globally, 13% of the world's adult population is obese, and more than 400 million people suffer from diabetes. These conditions are both associated with significant morbidity, mortality and financial cost. Therefore, finding new pharmacological treatments is an imperative. Relative hyperglucagonaemia is seen in all types of diabetes, and has been implicated in its pathogenesis. Consequently, clinical trials are underway using drugs which block glucagon activity to treat type 2 diabetes. Conversely, exogenous glucagon can increase energy expenditure. Therefore, researchers are designing peptides that combine activation of the glucagon receptor with further incretin properties, which will treat obesity while mitigating the hyperglycaemic effects of glucagon. This review will discuss these conflicting physiological properties of glucagon, and the attempts to harness these effects pharmacologically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.